Corbus Pharmaceuticals Holdings Inc. searched for efficacy in a Phase II cystic fibrosis study for its only clinical drug candidate, anabasum (JBT-101; resunab), but the signal highlighted by the company was found in a data point outside of the trial's pre-defined endpoints.
The clinical trial's primary endpoint sought acceptable safety and tolerability for the endocannabinoid-mimetic drug, which preferentially binds to the cannabinoid-2...